Gilead Sciences INC GILEAD SCIENCES ORD SHS
Gilead Sciences INC GILEAD SCIENC.../ US3755581036 /
0QYQ
24.05.2024 18:04:40
|
Zm.
-
|
Wolumen |
Bid18:30:00 |
Ask18:30:00 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
66,42USD
|
-
|
6 526 Obrót: 96 741,02 |
-Wolumen Bid: - |
-Wolumen Ask: - |
85,48 mldUSD |
4,37% |
15,11 |
Opis działalności
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Zarząd & Rada nadzorcza
CEO |
Daniel O’Day |
Zarząd |
Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Cindy Perettie, Deborah H. Telman, Merdad Parsey |
Rada nadzorcza |
Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Harish Manwani, Anthony Welters, Ted W. Love, Javier J. Rodriguez |
Dane firmy
Nazwa: |
Gilead Sciences Inc. |
Adres: |
333 Lakeside Drive,Foster City, California 94404, USA |
Telefon: |
+1-650-574-3000 |
Fax: |
+1-650-578-9264 |
E-mail: |
corporate_developmen...ad.com
corporate_development@gilead.com
|
Internet: |
www.gilead.com |
Przemysł: |
Służba zdrowia |
Sektor: |
Przemysł Farmaceutyczny |
Podsektor: |
Przemysł Farmaceutyczny |
Koniec roku finansowego: |
31.12 |
Free float: |
99,89% |
Data IPO: |
22.01.1992 |
Główni akcjonariusze
Inne |
|
55,84% |
Blackrock Inc. |
|
10,13% |
Vanguard Group Inc |
|
9,10% |
Capital World Investors |
|
6,50% |
State Street Corporation |
|
4,76% |
Capital Research Global Investors |
|
4,65% |
Dodge & Cox Inc |
|
2,73% |
Geode Capital Management, LLC |
|
1,94% |
FMR, LLC |
|
1,61% |
Inne |
|
2,74% |